Optibiotix PLC U Shaped Recovery Should Stretch To 30p Plus

OPTI Optibiotix PLC Technical Analysis 260115

 

After a nightmare plunge for the stock in 2013 it can be said quite fairly that shares of Optibiotix PLC (LON: OPTI) have morphed into a charting situation which effectively renders it a classic recovery play. This is one that ticks most of the best known boxes on the technical front. They include the 50 day /200 day moving average golden cross buy signal in November which followed the as yet untested break above the 200 day line now at 12.29p at the beginning of that month. That event really was the giveaway as far as signalling to us that Optibiotix would be the big winner over the near to medium term which it is starting to become. It helps that all of this positivity is coming in the wake of a post 2013 U shaped charting pattern, something which is usually the precursor of sustained bull runs.

But before we get too carried away with how solid the technical position here appears to be it may be best to at least develop a road map as to what may happen here over the next 1-2 months. The vehicle for the rise since the autumn has been a rising trend channel from March, one which has its floor based at the 50 day moving average now at 19p. This notional double support zone is the suggested weekly stop loss on the buy argument currently. The chances now are that while there is no weekly close below 19p the upside for Optibiotix as soon as the end of February could be towards the March resistance line at 32p. Once that is reached we may quickly find out how long this improvement may really continue.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    DirectorsTalk

    More articles like this

    Optibiotix Health Plc

    NutraIngredients Awards shortlist announced

    NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

    Optibiotix Health Plc

    OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

    Optibiotix Health Plc

    OptiBiotix Health PLC OptiBiotix Capital Reorganisation

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

    Optibiotix Health Plc

    Optibiotix Health PLC In a Strong Position

    Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

    Optibiotix Health Plc

    Functional weight loss ingredient, SlimBiome brought to US

    OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

    Optibiotix Health Plc

    SlimBiome® – Supporting hunger-free weight management

    Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

    Optibiotix Health Plc

    OptiBiotix Health PLC Proposed Directorate Changes

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

    Optibiotix Health Plc

    Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

    Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts:   “We are really